In this study, we presented two cases with BRCA1/2 LGR as determined by NGS (ovarian cancer case: BRCA1 germline exon 8-11 deletion; breast cancer case: BRCA1 germline exon 2 deletion), and both patients benefited from PARPi therapy, providing evidence for the feasibility and significance of NGS-based LGR detection in guiding treatment. This evidence concerns the gene BRCA1 and ovarian cancer.